- Motley Fool•yesterday
Tesaro's cancer-fighting drug, niraparib, nabbed FDA approval roughly three months ahead of schedule.
Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are ...
TSRO : Summary for TESARO, Inc. - Yahoo Finance
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||150.25 x 100|
|Ask||150.86 x 100|
|Day's Range||148.00 - 153.45|
|52 Week Range||36.68 - 192.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-18.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|